FILTER
LATEST ARTICLES
A West-Meets-East Of The Pharma Industry
January 31, 2020
Portrait of the Turkey Pharmaceuticals industry.
The 2020s: India’s decade?
November 19, 2019
As 2020 approaches, GBR takes a look at how far India has come to achieving its Pharma Vision 2020
Chile: Uncertainty Hits the Stalwart of Latin American Mining
November 12, 2019
Social turmoil returns to the streets of Santiago after 30 years of calm.
Ghana’s Push Towards Modernization and Innovation
November 12, 2019
Ghana must adapt to maintain its new title of the top gold producer in Africa.
An Industry in Decline: Understanding the Politics behind South Africa’s Downfall
October 02, 2019
Once the mining capital of Africa, South Africa’s decline in regional hegemony is inextricably linked to its fraught sociopolitical fabric.
Peru’s Junior Segment
September 10, 2019
Juniors have good projects to work on, but continue to suffer costly delays to obtain government permits.
Production and Exploration Highlights from the DRC
September 10, 2019
Copper, cobalt and lithium continue to rule the day in the heart of Africa.
U.S. Pharmaceuticals: The East Coast
July 25, 2019
From New England to the Mid-Atlantic, a rising tide lifts all boats across the biopharma value chain.
Mining Services in Peru
July 24, 2019
Investment in technology is driving efficiency across contracts.
The DRC’s Unparalleled Resource Potential
July 24, 2019
A look at the high-risk, high-reward resources in the heart of Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
